The orange stamp is an initiative of the SIU created to map and enhance the Italian healthcare offering in the field of uro-oncology, certifying the centers that operate according to the best international scientific evidence and through a truly multidisciplinary approach.
The Arnas Garibaldi Hospital in Catania officially joins the national reference centers for uro-oncology, earning the Orange Label from the Italian Society of Urology (SIU), a prestigious recognition awarded to facilities that ensure high quality standards in the diagnosis and treatment of kidney cancer. The Orange Label is an initiative of the SIU created to map and enhance the Italian healthcare offering in the field of uro-oncology, certifying centers that operate in accordance with the best international scientific evidence and adopt a truly multidisciplinary approach.
The certification, valid for the two-year period 2025–2026, is issued after a rigorous evaluation by a Board of urologists, radiologists, pathologists, and oncologists. This recognition recognizes a long-standing commitment and attests to the high quality of care provided by Arnas Garibaldi, confirming its position in the national landscape of highly specialized healthcare.
“The Orange Label,” states Professor Mario Falsaperla, Director of Urology, “represents a significant achievement that recognizes the daily work of the entire team. It confirms our ongoing commitment to innovation, multidisciplinary integration, and rigorous application of international guidelines, with a single goal: to ensure increasingly effective and safe treatment options for patients.”
The awarding of the Orange Label strengthens the Hospital’s visibility and credibility, making it increasingly attractive to patients and consolidating its role as a leading center for the management of complex uro-oncological conditions. The Strategic Management team also expressed satisfaction.
“This recognition,” says Giuseppe Giammanco, General Manager of Arnas Garibaldi, “is testament to the quality of the organization, the professional expertise, and the technological investments made by the company. It is a result that strengthens our position in the region and encourages us to continue our journey of continuous improvement of the services we offer to citizens.”
Beyond its healthcare value, the Orange Seal also opens up new perspectives for research and training, facilitating access to refresher programs and clinical trials promoted by the SIU. For Arnas Garibaldi, the recognition does not represent a point of arrival, but rather a significant milestone on a journey toward future development, quality of care, and patient-centeredness, within a modern, integrated healthcare system that is increasingly responsive to the needs of the population.